Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

NDAQ:PMN - Post Discussion

ProMIS Neurosciences Inc > New Preclinical Data
View:
Post by bball67 on Mar 23, 2023 12:31pm

New Preclinical Data

So, Promis put out a press release on March 13th saying they will present new preclinical data as part of their presentation in Europe and it would be available on the Promis website on March 28. So, I don't know why the headline of the press release would tout new preclinical data if it wasn't something important or significant. I hope it is not a dud.
Comment by BottomBroker on Mar 23, 2023 3:38pm
The folks at PMN seem to favor the "over-promise, under-deliver" approach. We'll see. 
Comment by M101 on Mar 29, 2023 7:28pm
Anyone here figure out what if any new preclinical data is worked into the poster? Because if not then I must invoke the famous (and last) mocking words of Cool Hand Luke: "What we have here is a failure to communicate" 
Comment by BottomBroker on Mar 30, 2023 9:12am
Seemed like more of the same to me. Don't get me wrong, less brain bleeding/fewer side effects are  definitely a reason for optimism, but I think we already knew that. Right?
Comment by retiredcop on Mar 29, 2023 11:35pm
Keep in mind this presentation is PMNs participation in a scientific capacity and it's for the benefit of scientists and researchers workin in the area of PD and AD.   So this information is new  scientific data that has been published after the last ad/ pd conference so it is new data.  This is different from news releases they make for the benefit of the media and investors. I ...more  
Comment by retiredcop on Mar 29, 2023 11:40pm
3.5 minutes to make their point and move on .. follow up information comes later with    One on one discussions and in this case most likely online or messaging.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities